Through multivariate regression analysis, we identified CHST12 and N staging as independent prognostic risk factors for OS in PAAD patients, which indicates that CHST12 may be useful in clinical settings as a prognostic biomarker and possesses potential clinical utility in PAAD patients. The gene discussed is CHST12; the disease is pancreatic adenocarcinoma.